Table 2.
Drugs being taken at recruitment by region
| Asia | EME | Eastern Europe | P* | |
|---|---|---|---|---|
| n | 4,136 | 4,862 | 2,142 | |
| ≥1 oral glucose–lowering drugs | 3,926 (94.9) | 4,280 (88.0) | 1,922 (89.8) | <0.0001 |
| Gliclazide | 159 (3.8) | 290 (6.0) | 416 (19.4) | <0.0001 |
| Sulphonylureas | 3,048 (73.7) | 2,828 (58.2) | 1,215 (56.7) | <0.0001 |
| Metformin | 2,639 (63.8) | 3,106 (63.9) | 1,007 (47.0) | <0.0001 |
| Thiazolidinedione | 98 (2.4) | 300 (6.2) | 9 (0.4) | <0.0001 |
| Arcabose | 595 (14.4) | 201 (4.1) | 164 (7.7) | <0.0001 |
| Glinide | 40 (1.0) | 120 (2.5) | 27 (1.3) | <0.0001 |
| Insulin therapy | 66 (1.6) | 50 (1.0) | 43 (2.0) | 0.06 |
| No glucose-lowering drugs | 191 (4.6) | 579 (11.9) | 218 (10.2) | <0.0001 |
| Aspirin | 1,734 (41.9) | 2,220 (45.7) | 941 (43.9) | 0.03 |
| Other antiplatelet agents | 168 (4.1) | 236 (4.9) | 102 (4.8) | 0.40 |
| Statins | 458 (11.1) | 2,170 (44.6) | 518 (24.2) | <0.0001 |
| Other lipid-modifying drugs | 370 (8.9) | 376 (7.7) | 190 (8.9) | 0.07 |
| Any blood pressure–lowering drugs | 2,812 (68.0) | 3,617 (74.4) | 1,936 (90.4) | <0.0001 |
Data are n (%) unless otherwise indicated.
*Adjusted for age, sex, and duration of diabetes.